Pull incentives to happen during 116th congress?
US stakeholders active in AMR have sent a letter to US congress representatives urging the need for pull incentives.
The letter was published in early February and signed by a broad coalition of stakeholders including SMEs, big pharma, and other organisations. It has been sent to all the relevant legislative committees: the Senate Committee on Health, Education, Labor & Pensions (HELP), the Senate Committee on Finance, the House Committee on Ways & Means, and the House Committee on Energy & Commerce.
After explaining the background and the need for a fundamental fix via a package of incentives, the letter highlights that:
- Incentives should be paid after FDA approval, rewarding only successful development of novel antibiotics that address the greatest public health need.
- A package of incentives should aim both to stabilize today’s novel antibiotic market and to ensure the viability of future development – meaning they must be substantial and viewed as highly valuable to private markets.
- Economic incentives should provide predictability for drug developers – assurance that the company can commit R&D funds today, knowing that the economic incentive will be available if the new drug meets eligibility criteria.
- Incentives must be aligned with appropriate antibiotic stewardship and surveillance.
In addition, the authors say: “We commit to working with Congress and the Administration to further develop and advance a package of antibiotic incentives, at least some of which must be enacted in 2019 to meet growing patient needs and help mitigate a public health crisis. Such a package could, for example, include a mix of tax incentives, novel pull incentives, reimbursement changes, and even a low-interest loan program, along with continued investment in NIAID and BARDA.”
According to experts, there is an active progress on a bipartisan bill that would be introduced to the House and Senate simultaneously in which a fundamental DRG fix is proposed as an initial step. Now, the stakeholders hope that a delinked reward model could follow in the future as well.
More Information: https://www.idsociety.org/globalassets/idsa/policy–advocacy/current_topics_and_issues/antimicrobial_resistance/10×20/legislative-efforts/020519-joint-letter-to-senate-help-and-finance-re-economic-incentives-for-antibiotics.pdf